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Abstract
Allogeneic  conventional  hematopoietic  cell  transplantation  (HCT)  following  high
myeloablative conditioning regimens has been used since the 1970’s as potentia
treatment for patients with malignant, hematological disorders. The toxicities of conditioning 
regimens  have  limited  conventional  HCT  to  relatively  young  patients  in  otherwise  good 
medical  condition.  With  the  development  of  less  toxic  nonmyelo
improvements in supportive care, increasing numbers of older and medically infirm patients 
have  been  treated  by  allogeneic  HCT.  Until  recently,  there  has  been  almost  no  effort  to 
evaluate  the  prevalence  of  comorbidities  among  HCT  reci
outcomes. We first evaluated the Charlson Comorbidity Index (CCI) developed for patients 
with solid malignancies, for this purpose. While useful, it lacked sensitivity and specificity for 
the HCT setting. We next introduced the H
was based on objective laboratory data to better define comorbidities. Here, we describe this 
development  and  illustrate  the  usefulness  of  the  HCT
patients with myeloid and lymphoid malignancies undergoing allogeneic transplantation
Introduction:  Allogeneic  conventional  HCT  is 
considered  potentially  curative  for  patients  with 
malignant or non-malignant hematological diseases. 
Conditioning regimens for conventional HCT have 
been intensified to the limits of organ tolerance in 
order to optimize disease eradication. Consequently, 
serious  toxicities  to  organs,  such  as  gut,  lung, 
kidney, heart, and liver have been observed which, 
additionally,  have  limited  the  ability  to  deliver 
adequate doses of postgrafting immunosuppression 
needed for control of GVHD. Until recently, these 
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Allogeneic  conventional  hematopoietic  cell  transplantation  (HCT)  following  high
myeloablative conditioning regimens has been used since the 1970’s as potentia
treatment for patients with malignant, hematological disorders. The toxicities of conditioning 
regimens  have  limited  conventional  HCT  to  relatively  young  patients  in  otherwise  good 
medical  condition.  With  the  development  of  less  toxic  nonmyeloablative  regimens  and 
improvements in supportive care, increasing numbers of older and medically infirm patients 
have  been  treated  by  allogeneic  HCT.  Until  recently,  there  has  been  almost  no  effort  to 
evaluate  the  prevalence  of  comorbidities  among  HCT  recipients  and  their  impact  on 
outcomes. We first evaluated the Charlson Comorbidity Index (CCI) developed for patients 
with solid malignancies, for this purpose. While useful, it lacked sensitivity and specificity for 
the HCT setting. We next introduced the HCT-specific comorbidity index (HCT
was based on objective laboratory data to better define comorbidities. Here, we describe this 
development  and  illustrate  the  usefulness  of  the  HCT-CI  in  predicting  HCT  outcomes  in 
oid malignancies undergoing allogeneic transplantation
Allogeneic  conventional  HCT  is 
considered  potentially  curative  for  patients  with 
malignant hematological diseases. 
Conditioning regimens for conventional HCT have 
been intensified to the limits of organ tolerance in 
se eradication. Consequently, 
serious  toxicities  to  organs,  such  as  gut,  lung, 
kidney, heart, and liver have been observed which, 
additionally,  have  limited  the  ability  to  deliver 
adequate doses of postgrafting immunosuppression 
Until recently, these 
regimen-related  toxicities  associated  with 
myeloablative conditioning have limited allogeneic 
HCT to patients without significant co
who were less than 55 to  60 years old.  This age 
restriction  has  been  unfortunate  since  t
ages  of  patients  with  most  candidate  diseases  for 
HCT,  e.g.,  acute  and  chronic  leukemias, 
myelodysplasia  (MDS),  multiple  myeloma,  and 
lymphomas, have ranged from 65 to 70 years.
In  an  effort  to  expand  treatment  options  for 
patients with hematological malignancies and based 
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Allogeneic  conventional  hematopoietic  cell  transplantation  (HCT)  following  high-dose, 
myeloablative conditioning regimens has been used since the 1970’s as potentially curative 
treatment for patients with malignant, hematological disorders. The toxicities of conditioning 
regimens  have  limited  conventional  HCT  to  relatively  young  patients  in  otherwise  good 
ablative  regimens  and 
improvements in supportive care, increasing numbers of older and medically infirm patients 
have  been  treated  by  allogeneic  HCT.  Until  recently,  there  has  been  almost  no  effort  to 
pients  and  their  impact  on 
outcomes. We first evaluated the Charlson Comorbidity Index (CCI) developed for patients 
with solid malignancies, for this purpose. While useful, it lacked sensitivity and specificity for 
specific comorbidity index (HCT-CI) which 
was based on objective laboratory data to better define comorbidities. Here, we describe this 
CI  in  predicting  HCT  outcomes  in 
oid malignancies undergoing allogeneic transplantation.
related  toxicities  associated  with 
myeloablative conditioning have limited allogeneic 
HCT to patients without significant co-morbidities 
who were less than 55 to 60 years old.  This  age 
restriction  has  been  unfortunate  since  the  median 
ages  of  patients  with  most  candidate diseases  for 
HCT,  e.g.,  acute  and  chronic  leukemias, 
myelodysplasia  (MDS),  multiple  myeloma,  and 
lymphomas, have ranged from 65 to 70 years.
In  an  effort  to  expand  treatment  options  for 
ical malignancies and based Medit J Hemat Infect Dis 2010; 2(2): Open Journal System
on results from a series of canine studies,
1-4 a truly 
nonmyeloablative  regimen  of  2  Gy  TBI  with  or 
without fludarabine, 90 mg/m
2, has been introduced 
to  older  and  medically  infirm  patients  before 
allogeneic HCT from related or unrelated donors.
5,6
The  conditioning  regimen’s  major role  has  been 
host  immunosuppression.  Effective  postgrafting 
immunosuppression with MMF and CSP has been 
crucial  in  this  approach  with  the  aim  of  both 
enhancing  hematopoietic  engraftment  and 
controlling  GVHD.  There  has  been  little  direct 
antitumor  effect  from  the  conditioning  regimen. 
Instead, the approach has relied predominantly on 
the  generation  of  donor  T  cell  (and/or  NK  cell)-
mediated graft-versus-tumor effects for eradication 
of  cancer.  The  use  of  this  nonmyeloablative 
regimen has expanded the use of HCT to include 
elderly and medically infirm patients with various 
hematological disorders.
7-9
Age has been frequently cited as an important
prognostic variable in HCT. Historical age cutoffs 
have  been  55  and  60  years,  respectively,  largely 
influenced by the type of HCT donor (related versus 
unrelated). The reason for the age cutoffs has been 
prohibitive regimen-related toxicity and mortality in 
older patients. It has also been suggested that older 
patients were at higher risk of GVHD resulting in 
worse  survivals.  Most  reports  on  age  and  HCT 
outcomes,  however,  have  ignored  comorbidities, 
which  might  have  been  confounding  factors. 
Several  investigators  have  studied  single  organ 
comorbidities  in  the  context  of  predicting  same 
organ  toxicity  after  HCT.  Comprehensive 
assessment  of  the  interaction  between  multiple 
comorbidities and their impacts on HCT outcomes 
has  become  increasingly  important  given both 
increasing age of the Western population along with 
increasing prevalence of cancer and comorbidities
10
and the increasing enrollment of patients aged >60 
years in HCT clinical trials.
11  
Comorbidities  using the Charlson  Comorbidity 
Index (CCI): In the field of cancer, investigators 
have  found  variable  interactions  between  a  given 
primary  disease and  different  comorbidities based 
on type and severity of organ involvements. As a 
result, several indices have been created to rate the 
impacts  of  different  comorbidities  on  the  primary 
disease.  The  Charlson  Comorbidity  Index  (CCI)
12
included 19 comorbidities which have been selected 
and weighted based on their strength of associations 
with mortality. The CCI has been the most widely 
used comorbidity index to predict mortality risks in 
various solid malignancies
13-21. 
We  used  the  CCI  in  a  retrospective  study  to 
compare  pretransplant  comorbidity  differences 
among recipients of  nonmyeloablative (n=60) and 
myeloablative HCT (n=72) from unrelated donors.
22
At the time of HCT, nonmyeloablative patients had 
more often high-risk diseases (P=0.02); were older 
(median age,  54  versus  41  years,  P<0.0001);  had 
more preceding chemotherapy regimens (3 versus 1, 
P=0.01); had more frequently failed myeloablative 
HCT  (P<0.0001);  and  received  more  often 
peripheral  blood stem cell  grafts (P<0.0001) than 
myeloablative  patients.  In  addition, 
nonmyeloablative  patients  had  higher  CCI  scores 
compared to myeloablative patients (scores of 1-2 
and  3, 35% and 18% compared to 12% and 0%, 
respectively, P<0.0001) at the time of HCT. 
After HCT, nonmyeloablative patients experienced 
less  gastrointestinal  (P<0.0001),  hepatic (P=0.02), 
hemorrhagic  (P=0.005),  infectious  (P=0.09),  and 
metabolic (P=0.03) grades III-IV toxicities. Further, 
there were trends for less neurological, renal, and 
pulmonary grades III-IV toxicities (P=0.1 for each). 
In  particular,  nonmyeloablative  patients  had  less 
(32% versus 69%, P<0.0001) overall grade IV (life-
threatening) toxicities  than  myeloablative patients. 
No  single  cases  of  veno-occlusive  disease  or 
mucositis  was  detected  among  nonmyeloablative 
compared  to  18%  and  72%  among  myeloablative 
patients,  respectively.  Also,  nonmyeloablative 
patients experienced less grades III-IV acute GVHD 
(P=0.03).  The  lessened  cumulative  incidences  of 
day 100 (12% versus 18%, P=1.4) and 1-year (20% 
versus 32%, P=1.4) NRM among nonmyeloablative 
patients did not reach statistical significance. After 
adjustment for  pretransplant differences,  including 
comorbidity  scores,  statistically  suggestive  or 
significant  lower  hazard  ratios  (HR)  for  day  100 
(0.2, P=0.07) and 1-year (0.3, P=0.04) NRM were 
found for nonmyeloablative patients, confirming the 
importance  of  a  single  scoring  system  for 
comorbidities.  In  multivariate  analyses  of  risk 
factors for outcomes, comorbidities as scored by the 
CCI, proved to be the only independent factor for 
predicting overall grade IV toxicity (HR were 2.9 
and 5.5 for scores 1-2 and ≥ 3, respectively, p=0.06) 
and  NRM  (HR  were  2.4  and  10.5,  respectively, 
p=0.04).  Cumulative incidence  and Kaplan  Maier 
curves showed linear increases in overall grade IV 
toxicities,  NRM,  and  worsening  survival  with 
increasing  CCI  scores,  whereby  better  outcomes 
were observed among nonmyeloablative compared 
to myeloablative patients with similar CCI scores. 
In  a  concurrent  study,  the  CCI  was  important  in 
predicting NRM among recipients of HLA-matched 
related HCT.
23Medit J Hemat Infect Dis 2010; 2(2): Open Journal System
Figure 1: NRM and survival by HCT-CI scores among patients of the validation set.
24 Patients with HCT-CI scores of 0, 1-2, and ≥ 3 
had cumulative incidences of NRM of 14%, 21%, and 41% and survival rates of 71%, 60%, and 34%, respectively. 
This research was originally published in Blood. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, Storer B. 
Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 
2005;106(8):2912-9. © the American Society of Hematology.
An  HCT-specific  comorbidity  index  (HCT-CI): 
The  CCI  lacked  sensitivity  in  detecting  several 
comorbidities  among  HCT  recipients,  given  that 
scores  >0  were  detected  among  only  35%  of  all 
HCT  patients  (12%  among  myeloablative 
patients).
22 This was thought to be due to not well-
defined definitions of some comorbidities, such as 
hepatic  and  pulmonary.  In  addition,  relatively 
frequent comorbidities among HCT patients, such 
as infections, were not included in the CCI.
In  order  to  improve  sensitivity,  a  study  was 
designed  which  included  1055  consecutive 
recipients  of  allogeneic  HCT  between  1998  and 
2004 who had various hematological diseases, and 
of  whom 249 received nonmyeloablative and 761 
myeloablative conditioning. Patients were randomly 
assigned to training (n=708) and validation (n=347) 
sets.
24 Novel definitions were modeled for hepatic 
and renal comorbidities by using actual laboratory 
data and for pulmonary and cardiac comorbidities 
by using test results of organ function. Also, new 
integer  weights  of  comorbidities  were  calculated 
based on HRs from Cox proportional hazard models 
of  2-year  NRM,  which  were  adjusted for  disease 
risk, age, and conditioning regimen intensity. The 
new  HCT-CI  consisted  of  17  comorbidities 
including  three  comorbidities  that  were  not 
represented  in  the  CCI,  obesity,  peritransplant 
infections,  and  psychiatric  disturbances.  HCT-CI 
scores of 0, 1, 2, 3, and ≥ 4 predicted 2-year NRM 
of  9%,  14%,  27%,  41%,  and  43%,  respectively, 
among patients of the training set. 
When applied to data from the validation set, 
HCT-CI scores of 1-2 and ≥ 3 were found in 34% 
and 28% of patients compared to CCI scores of 1 
and   2  in  only  10%  and  3%  of  patients, 
respectively. Most importantly, HCT-CI scores of 0, 
1-2,  and  ≥ 3  showed  linear  predictions  of  NRM 
(14%, 21%, and 41%) and survival (71%, 60%, and 
34%), respectively (Figure 1). In addition, HCT-CI 
scores  had  higher  discriminative  power  than  CCI 
scores  both  for  NRM  (c  statistic  of  0.692  versus 
0.546, P < 0.001) and survival (c statistic of 0.661 
versus 0.561, P < 0.001).
HCT-CI  and  outcomes  after  conditioning 
regimens of different intensities: 
Patients with acute myeloid leukemia (AML) or 
myelodysplasia  (MDS).  We  compared  outcomes 
among  patients  with  AML  (n=391)  or  MDS 
(n=186) given either nonmyeloablative (n=125) or 
myeloablative HCT (n=452).
25 The median age of 
nonmyeloablative patients was 60 years compared 
to  46  years  among  myeloablative  patients.  In  an 
initial analysis of outcomes among all patients, high 
HCT-CI scores and high disease risk independently 
predicted  non-relapse  mortality  (NRM,  p<0.0001 
and p=0.004), overall survival (OS, p<0.0001 and 
p<0.0001),  and  relapse-free  survival  (RFS, 
p<0.0001 and p<0.0001), respectively. This allowed 
us to divide patients intofour risk groups based both 
on comorbiditiesand disease risks (Table 1). 
Cumulative  incidences  of  NRM  tended  to  be 
lower  and  relapse  rates  higher  among 
nonmyeloablative  compared  to  myeloablative 
patients  resulting  in  comparable  rates  of  OS  and 
RFS  across  all  risk  groups,  even  though 
nonmyeloablative  patients  were  older  than  those 
given myeloablative conditioning. Novel anti-tumor 
agents  combined  with  nonmyeloablative  HCT 
should  be  explored  among  patients  with  high 
comorbidity scores and advanced disease.
25
Patients  with  lymphoma  or  chronic  lymphocytic 
leukemia (CLL).  Myeloablative allogeneic HCT has 
been associated with high regimen-related mortality 
(up  to  60%)  among  patients  withMedit J Hemat Infect Dis 2010; 2(2): Open Journal System
Table 1: Two-year NRM, relapse, OS, and RFS incidences among 4 risk groups of nonmyeloablative and myeloablative patients 
with AML or MDS. Donors were either related (n=301) or unrelated (n=276).
25
Risk groups Patients NRM (%) Relapse (%) OS (%) RFS (%)
Group I 
(HCT-CI scores 0-2 and low-risk 
diseases)
Myeloablative (n=138) 11 14 78 75
Nonmyeloablative (n=28) 4 33 70 63
Group II 
(HCT-CI scores 0-2 and intermediate 
and high-risk diseases)
Myeloablative (n=176) 24 34 51 43
Nonmyeloablative (n=34) 3 42 57 56
Group III 
(HCT-CI scores ≥ 3 and low-risk 
diseases)
Myeloablative (n=52) 32 27 45 41
Nonmyeloablative (n=19) 27 37 41 36
Group IV 
(HCT-CI scores ≥ 3 and intermediate 
and high-risk diseases)
Myeloablative (n=86) 46 34 24 20
Nonmyeloablative (n=44) 29 49 29 23
Reprinted with permission. © 2008 American Society of Clinical Oncology. Sorror, M. L. et al. J Clin Oncol; 26:4912-4920 2008.
lymphoma or CLL.
26-29 In order to get around this 
problem,  nonmyeloablative  conditioning  regimens 
have  been  explored.  A  recent  analysis  compared 
outcomes among 152 older (median age, 60 years) 
patients  given  nonmyeloablative  conditioning  to 
those  among  68  younger  (median  age,  46  years) 
patients  given  myeloablative  conditioning, 
stratifying for the HCT-CI.
30
We found that patients without comorbidities 
both  in  the  nonmyeloablative  and  myeloablative 
cohorts  had  comparable  NRM,  OS,  and 
progression-free  survivals  (Figure  2).  However,
Figure 2: Cumulative incidence estimates of NRM and Kaplan Meier survival estimates among nonmyeloablative compared to 
myeloablative patients with lymphoma or CLL and HCT-CI score 0.
30 NRM (18% versus 15%; respectively, P = 0.74) and OS (68% 
versus 60%; respectively; P = 0.75) were comparable among nonmyeloablative patients with HCT-CI scores of 0 compared to 
myeloablative patients. Differences remained statistically not significant (HR: 0.90; P = 0.91 and HR: 1.94; P = 0.27, respectively) 
after adjustment for other risk factors. 
This research was originally published in Blood. Sorror ML, Storer BE, Maloney DG, Sandmaier BM, Martin PJ, Storb R. Outcomes
after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of 
lymphoma and chronic lymphocytic leukemia. Blood. 2008; 111(1):446-52.  © the American Society of Hematology.
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Figure 3: Cumulative incidence estimates of NRM and Kaplan Meier survival estimates among nonmyeloablative compared to 
myeloablative patients with lymphoma or CLL and HCT-CI score ≥1.
30 NRM was statistically significantly lessened (28% versus 
50%; respectively, P = 0.009) and OS rates were more favorable (47% versus 35%; respectively; P = 0.04) among nonmyeloablative 
patients with HCT-CI scores of ≥1 compared to myeloablative patients. Further, differences became more significant for NRM (HR: 
0.19; P < 0.001) and OS (HR: 0.33; P = 0.007) after adjustment for other risk factors. 
This research was originally published in Blood. Sorror ML, Storer BE, Maloney DG, Sandmaier BM, Martin PJ, Storb R. Outcomes
after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of 
lymphoma and chronic lymphocytic leukemia. Blood. 2008; 111(1):446-52.  © the American Society of Hematology.
nonmyeloablative  patients  with  comorbidities  had 
lower NRM (p = 0.009) and better OS (p = 0.04) 
than  myeloablative  patients  (Figure  3).  These 
differences became more significant after adjusting 
for  other  variables;  also  adjusted  progression-free 
survival  was better  (p = 0.01). This  suggests that 
younger patients with comorbidities would benefit 
from reducing conditioning intensity.
Conclusions:  The  HCT-CI  provided  simple  and 
reliable scoring of pre-transplant comorbidities that 
predicted NRM and survival. The index still needs 
validation  among larger  patient  samples in  multi-
center settings. Comorbidity data used in the index 
will likely become as important as defining cancer 
diagnosis,  disease  stage  and  other,  more  familiar 
prognostic variables.
31  
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